CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $1.43B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 1.85: grey zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
16.30BUSDvs all stocks (USD)
Trailing P/E
18.09xvs Biotechnology peers
Revenue (TTM)
4.60BUSDvs all stocks (USD)
Profit Margin
20.45%vs Biotechnology peers
Beta
0.3640xvs all stocks
52-Week Change
98.96%vs all stocks
Market Capitalization
16.30BUSDvs all stocks (USD)
Enterprise Value
18.73BUSDvs all stocks (USD)
Trailing P/E
18.09xvs Biotechnology peers
Forward P/E
10.25xvs Biotechnology peers
PEG Ratio
-0.1436xvs Biotechnology peers
Price to Sales (TTM)
3.73xvs Biotechnology peers
Price to Book (MRQ)
3.57xvs Biotechnology peers
Enterprise to Revenue
4.07xvs Biotechnology peers
Enterprise to EBITDA
9.72xvs Biotechnology peers
Gross Margin
90.37%vs Biotechnology peers
Profit Margin
20.45%vs Biotechnology peers
Operating Margin
26.91%vs Biotechnology peers
Return on Assets (TTM)
6.86%vs Biotechnology peers
Return on Equity (TTM)
22.11%vs Biotechnology peers
Revenue (TTM)
4.60BUSDvs all stocks (USD)
Revenue per Share (TTM)
74.60USDUpdated Aug 27, 2026Quarterly Revenue Growth
15.50%vs Biotechnology peers
Gross Profit (TTM)
4.20BUSDvs all stocks (USD)
EBITDA (TTM)
1.73BUSDvs all stocks (USD)
Net Income (TTM)
940.75MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.55%vs Biotechnology peers
Operating Cash Flow (TTM)
1.66BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
1.43BUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.27BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
503.30MUSDFY2025 · Dec 31, 2025Gross Profit
3.76BUSDFY2025 · Dec 31, 2025Operating Income
517.62MUSDvs all stocks (USD)
Pre-tax Income
-627.86MUSDFY2025 · Dec 31, 2025Income Tax Expense
-272.44MUSDFY2025 · Dec 31, 2025Net Income
-356.15MUSDFY2025 · Dec 31, 2025EBIT
-432.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.21BUSDFY2025 · Dec 31, 2025Research & Development
782.74MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.81BUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
195.05MUSDFY2025 · Dec 31, 2025EPS (Basic)
-5.84USDFY2025 · Dec 31, 2025EPS (Diluted)
-5.84USDFY2025 · Dec 31, 2025Basic Shares Outstanding
60.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
60.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-356.15MUSDFY2025 · Dec 31, 2025Operating Cash Flow
1.19BUSDFY2025 · Dec 31, 2025Free Cash Flow
1.13BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.39BUSDFY2025 · Dec 31, 2025Income Tax Paid
121.81MUSDFY2025 · Dec 31, 2025Interest Paid
248.55MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-356.15MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
696.30MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-444.97MUSDFY2025 · Dec 31, 2025Stock-based Compensation
291.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.13BUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-106.28MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
39.85MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-58.02MUSDFY2025 · Dec 31, 2025Capital Expenditures
-58.75MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-151.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
-858.05MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.83BUSDFY2025 · Dec 31, 2025Sale of Investments
1.36BUSDFY2025 · Dec 31, 2025Other Investing Activity
28.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.36BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-781.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-125.02MUSDFY2025 · Dec 31, 2025Other Financing Charges
-75.22MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-981.24MUSDFY2025 · Dec 31, 2025Shares Outstanding
64.80MSharesUpdated Aug 27, 2026Float Shares
62.94MSharesUpdated Aug 27, 2026Shares Short
3.36MSharesUpdated Aug 27, 2026Short Ratio
4.65daysvs all stocks
Short % of Shares Outstanding
5.32%vs all stocks
% Held by Insiders
2.99%vs all stocks
% Held by Institutions
103.04%vs all stocks
Total Cash (MRQ)
2.20BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
33.89USDUpdated Aug 27, 2026Total Debt (MRQ)
4.41BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9183xvs Biotechnology peers
Current Ratio (MRQ)
1.78xvs Biotechnology peers
Book Value per Share (MRQ)
74.10USDUpdated Aug 27, 2026Total Assets
11.66BUSDvs all stocks (USD)
Total Current Assets
4.17BUSDFY2025 · Dec 31, 2025Total Liabilities
7.34BUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.49BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.10BUSDFY2025 · Dec 31, 2025Total Current Liabilities
2.24BUSDFY2025 · Dec 31, 2025Cash
682.75MUSDFY2025 · Dec 31, 2025Cash Equivalents
709.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.39BUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.05BUSDFY2025 · Dec 31, 2025Accounts Receivable
830.75MUSDFY2025 · Dec 31, 2025Inventory
416.96MUSDFY2025 · Dec 31, 2025Accounts Payable
122.06MUSDFY2025 · Dec 31, 2025Short-term Debt
1.04BUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.22MUSDFY2025 · Dec 31, 2025Long-term Debt
4.38BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
124.52MUSDFY2025 · Dec 31, 2025Common Stock (Book)
61.00KUSDFY2025 · Dec 31, 2025Retained Earnings
646.18MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.32BUSDvs all stocks (USD)
52-Week Low
123.88USDUpdated Aug 27, 202652-Week High
266.38USDUpdated Aug 27, 202652-Week Change
98.96%vs all stocks
Beta
0.3640xvs all stocks
50-Day MA
245.12USDUpdated Aug 27, 2026200-Day MA
200.63USDUpdated Aug 27, 2026Avg 10-Day Volume
450.58KSharesUpdated Aug 27, 2026Avg 30-Day Volume
694.29KSharesUpdated Aug 27, 2026Diluted EPS (TTM)
14.61USDUpdated Aug 27, 2026Other Income / Expense
-950.43MUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.85: grey zoneSignificant
Altman Z-Score: 1.85
High earnings qualityNotable
Earnings Quality Score: 1.98
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $1.43B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 1,429,392,896Global P95: 1,235,197,352.727
Market cap is $16.3B, above the global median of $1.18BNotable
Market cap (USD): 16,300,699,430Global Median: 1,179,398,897.704
Revenue is $4.6B, above the global median of $534.05MNotable
Revenue (USD): 4,601,286,144Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
Sino Biopharmaceutical Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neurocrine Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ipsen S.A.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Pharma, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Biokin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sonova Holding AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Viatris Inc.
Tier 1ProductionApproval-Gated PipelineRule
Exelixis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zimmer Biomet Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Reservoir Media, Inc.
6 interpretationsCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked ROA and Margin ElevatedIntangible ConcentrationThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
6 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked ROA and Margin ElevatedThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year FCF With Growth And Margin
SJS Enterprises Ltd.
6 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked ROA and Margin ElevatedThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year FCF With Growth And Margin